Novartis’ Data-Centric R&D Strategy Adds Pact With UK-based Big Data Institute
Novartis and the Big Data Institute have entered a research alliance using artificial intelligence to understand complex diseases and improve drug development.
You may also be interested in...
Novartis executives highlighted their stars from its refined pipeline during the company’s first R&D day since Vas Narasimhan took the helm and after a cull that reduced the firm’s development portfolio by 20%.
Novartis is to move its UK headquarters to London to be at the heart of the new technology and life sciences in the west of the city.
Vas Narasimhan says it’s not enough to develop drugs that are first- or best-in-class, they have to be transformational in the benefits they offer patients and society at large. CAR-T therapy Kymriah fits the bill.